Hepion Pharmaceuticals (HEPA) Competitors $0.05 -0.02 (-24.03%) As of 12:54 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HEPA vs. AKAN, SLRX, ONCT, PBLA, ADXS, BPTH, VAXX, PTEIQ, ASLN, and CWBRShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Akanda (AKAN), Salarius Pharmaceuticals (SLRX), Oncternal Therapeutics (ONCT), Panbela Therapeutics (PBLA), Ayala Pharmaceuticals (ADXS), Bio-Path (BPTH), Vaxxinity (VAXX), PolarityTE (PTEIQ), ASLAN Pharmaceuticals (ASLN), and CohBar (CWBR). These companies are all part of the "pharmaceutical products" industry. Hepion Pharmaceuticals vs. Its Competitors Akanda Salarius Pharmaceuticals Oncternal Therapeutics Panbela Therapeutics Ayala Pharmaceuticals Bio-Path Vaxxinity PolarityTE ASLAN Pharmaceuticals CohBar Akanda (NASDAQ:AKAN) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations. Does the MarketBeat Community prefer AKAN or HEPA? Hepion Pharmaceuticals received 21 more outperform votes than Akanda when rated by MarketBeat users. CompanyUnderperformOutperformAkandaN/AN/AHepion PharmaceuticalsOutperform Votes2167.74% Underperform Votes1032.26% Is AKAN or HEPA more profitable? Akanda's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AkandaN/A N/A N/A Hepion Pharmaceuticals N/A -812.56%-207.31% Which has higher valuation & earnings, AKAN or HEPA? Akanda has higher revenue and earnings than Hepion Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkanda$836.66K2.35-$32.28MN/AN/AHepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00 Do insiders and institutionals believe in AKAN or HEPA? 1.0% of Akanda shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 20.4% of Akanda shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer AKAN or HEPA? In the previous week, Akanda had 1 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 2 mentions for Akanda and 1 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 1.00 beat Akanda's score of 0.36 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Akanda Neutral Hepion Pharmaceuticals Positive Which has more volatility and risk, AKAN or HEPA? Akanda has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. SummaryAkanda beats Hepion Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$581K$6.92B$5.59B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.018.8527.2120.00Price / SalesN/A261.39411.62157.76Price / CashN/A65.8538.2534.64Price / Book0.046.597.114.70Net Income-$48.93M$144.20M$3.24B$248.05M7 Day PerformanceN/A3.53%2.54%2.51%1 Month PerformanceN/A10.82%8.76%6.17%1 Year PerformanceN/A3.87%31.37%13.72% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion Pharmaceuticals1.2927 of 5 stars$0.05-24.0%N/A-99.9%$581KN/A-0.0120Short Interest ↓Gap UpAKANAkandaN/A$1.18-0.8%N/A-74.0%$1.68M$836.66K0.00110News CoveragePositive NewsShort Interest ↓SLRXSalarius Pharmaceuticals0.9232 of 5 stars$0.78+2.6%N/A-78.3%$1.67MN/A-0.1020ONCTOncternal TherapeuticsN/A$0.53flat$10.00+1,799.0%N/A$1.56M$790K-0.0530PBLAPanbela Therapeutics0.0869 of 5 stars$0.30+16.3%N/A-41.6%$1.46MN/A0.006Negative NewsShort Interest ↑Gap DownADXSAyala PharmaceuticalsN/A$0.03-2.6%N/AN/A$1.42M$3.24M0.0020BPTHBio-Path2.1447 of 5 stars$0.16-5.3%$20.00+12,322.4%-91.2%$1.34MN/A0.0010Short Interest ↑VAXXVaxxinityN/A$0.01flatN/A-90.2%$1.27MN/A-0.0290Gap DownPTEIQPolarityTEN/AN/AN/AN/A$1.24M$810K-0.0560Gap UpASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330CWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010 Related Companies and Tools Related Companies AKAN Alternatives SLRX Alternatives ONCT Alternatives PBLA Alternatives ADXS Alternatives BPTH Alternatives VAXX Alternatives PTEIQ Alternatives ASLN Alternatives CWBR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HEPA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HEPA Stock Free HEPA Stock Alerts